Compare MasTec Inc (MTZ) vs 10X Genomics Inc (TXG) Price & Performance

MasTec (MTZ) trades at $336.61, up 2.13% today, amid strong analyst sentiment with 32 of 36 analysts rating it a Buy. The stock shows robust fundamentals with Q1 2026 EPS beating estimates by 40.6% and a record $20.3 billion backlog. Recent $1.65 billion acquisition of The Superior Group enhances data center infrastructure capabilities, positioning MTZ for AI-driven power demand growth. Technical indicators are bearish overall, with the stock trading near pivot point resistance at $338.

Outlook remains positive given earnings momentum and strategic expansion, though high P/E of 58.95 poses valuation risk. Upside to consensus price target of $497.45 offers 47.8% potential, but investors face execution risks from integration and debt-funded acquisitions. Revenue growth to $15.3 billion in 2026 supports bullish thesis if margins hold.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.